Shots:

• The P-Ia/Ib trial is of ZL-1310 in ES-SCLC patients treated with at least one Pt-based CT regimen. Data included findings from 25 patients in the ongoing Part 1a monotx. dose-escalation study in 4 dose cohorts (0.8mg/kg, 1.6mg/kg, 2mg/kg & 2.4mg/kg)
• Study from 19 of them having evaluable tumor showed ORR of 74% in all dose levels, responses were observed in those with DLL3 H-scores from 5 & not in those without DLL3 expression and DoR was not-estimable at 2.4mos. follow-up
• Furthermore, 13/14 responders remain on treatment with the longest ongoing at 6.5+ mos.; PR was seen in all 6 response-evaluable patients with baseline brain metastases; 1 who progressed after prior DLL3 bi-specific therapy had PR at the 1st tumor assessment

Ref: Zai Lab | Image: Zai Lab

Related News:- Zai Lab and argenx Report the NMPA’s Approval of Efgartigimod Alfa SC Injection to Treat Generalized Myasthenia Gravis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com